| I. Background | |||||||||||||||||||||||||||||||||||||||||||||||
| Tumor mutational burden (TMB) shows great promise as a biomarker for immuno-oncology (I-O) therapy response, but progress is hindered by the lack of a standardized TMB measurement by targeted NGS panels, and an absence of TMB reference materials. 
 
 
 
 
 
 | |||||||||||||||||||||||||||||||||||||||||||||||
 
             
                            
 
             
             
         
             
             
             
             
             
             
            